

# Acute lymphoblastic leukemia: Causes, symptoms, diagnosis and treatment options.

Stephene Blair\*

Department of Hematology, New York University Perlmutter Cancer Center, New York, USA

**Received:** 26-Apr-2023, *Manuscript No.* AAMOR-23-97072; **Editor assigned:** 28-Apr-2023, *AAMOR-23-97072 (PQ)*; **Reviewed:** 12-May-2023, *QC No.* AAMOR-23-97072; **Revised:** 27-Jun-2023, *Manuscript No.* AAMOR-23-97072 (R); **Published:** 04-Jul-2023, *DOI:10.35841/aamor.7.5.191*

---

## Introduction

Acute Lymphoblastic Leukemia (ALL) is a type of cancer that affects the blood and bone marrow, causing an overproduction of immature white blood cells called lymphoblasts [1-3]. These abnormal cells can quickly multiply and crowd out healthy blood cells, leading to a range of symptoms and complications [4,5].

## Description

### Causes

The exact cause of ALL is unknown, but several risk factors have been identified. These include:

**Genetics:** Certain genetic mutations can increase the risk of developing ALL, although most cases occur sporadically without a known genetic cause.

**Environmental factors:** Exposure to certain chemicals and radiation has been linked to an increased risk of ALL.

**Medical history:** People who have received chemotherapy or radiation therapy for other cancers may have an increased risk of developing ALL.

### Symptoms

The symptoms of ALL can vary depending on the stage of the disease and the extent of the bone marrow involvement. Common symptoms may include:

- Fatigue, weakness and shortness of breath.
- Fever and chills.
- Frequent infections.
- Easy bruising and bleeding.
- Swollen lymph nodes, liver or spleen.
- Bone and joint pain.
- Loss of appetite and weight loss.
- Headaches, seizures and other neurological symptoms in rare cases.

### Diagnosis

Diagnosis of ALL typically involves several tests, including:

**Blood tests:** These can reveal abnormalities in the number and function of blood cells.

**Bone marrow biopsy:** A small sample of bone marrow is removed and examined under a microscope to look for abnormal cells.

**Imaging tests:** X-rays, CT scans and other imaging tests may be used to check for enlarged organs or other signs of leukemia.

### Treatment

Treatment for ALL typically involves a combination of chemotherapy and other medications. The specific drugs used will depend on the patient's age, overall health and other factors. Stem cell transplantation may also be considered in some cases, especially if the cancer does not respond to initial treatment or if the patient has a high risk of relapse. In addition to medical treatment, patients with ALL may benefit from supportive care, such as:

- Pain management.
- Nutritional support.
- Counseling and psychological support.
- Physical therapy and rehabilitation.

### Conclusion

Acute lymphoblastic leukemia is a serious condition that requires prompt diagnosis and treatment. With advances in medical technology and research, the prognosis for many patients with ALL has improved in recent years. However, early detection and prompt treatment remain key factors in achieving the best possible outcome. If you or a loved one is experiencing symptoms of ALL, it is important to speak with a healthcare provider as soon as possible.

### References

1. Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. *Mayo Clin Proc.* 2016;91(11):1645-66.
2. Jabbour E, O'Brien S, Konopleva M, et al. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. *Cancer.* 2015;121(15):2517-28.
3. Chessells JM, Harrison G, Richards SM, et al. Down's syndrome and acute lymphoblastic leukaemia: Clinical features and response to treatment. *Arch Dis Child.* 2001;85(4):321-5.

4. Sehgal S, Mujtaba S, Gupta D, et al. High incidence of Epstein Barr virus infection in childhood acute lymphocytic leukemia: A preliminary study. *Indian J Pathol Microbiol.* 2010;53(1):63-7.
5. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase activating lesions in Ph-like acute lymphoblastic leukemia. *N Engl J Med.* 2014;371(11):1005-15.

**\*Correspondence to**

Stephene Blair

Department of Hematology,

New York University Perlmutter Cancer Center,

New York,

USA

E-mail: [stephene.blair747@edu.org](mailto:stephene.blair747@edu.org)